SCHEMBL1475159

SCHEMBL1475159

O=C(NCCc1ccncc1)c1cc(-c2ccc(O)cc2)on1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 7/20 0.68
TP53 P04637 2/20 0.67
HDAC3 O15379 1/20 0.66
HDAC4 P56524 1/20 0.66
HDAC1 Q13547 1/20 0.66
HDAC7 Q8WUI4 1/20 0.66
HDAC2 Q92769 1/20 0.66
HDAC10 Q969S8 1/20 0.66
HDAC11 Q96DB2 1/20 0.66
HDAC8 Q9BY41 1/20 0.66
HDAC6 Q9UBN7 1/20 0.66
HDAC9 Q9UKV0 1/20 0.66
HDAC5 Q9UQL6 1/20 0.66
KDM4E B2RXH2 1/20 0.59
NPC1 O15118 1/20 0.59
RAB9A P51151 1/20 0.59
MAPT P10636 3/20 0.56
ALDH1A1 P00352 2/20 0.55
LMNA P02545 1/20 0.55
HPGD P15428 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1475769 0.89 HDAC6 (0.68) FAAHTP53HDAC3HDAC4HDAC1
SCHEMBL1474540 0.89 FAAH (0.67) FAAHTP53HDAC3HDAC4HDAC1
SCHEMBL1474935 0.89 FAAH (0.81) FAAHHDAC3HDAC1HDAC2HDAC10
SCHEMBL1474945 0.87 MAPT (0.64) FAAHTP53NPC1RAB9AMAPT
SCHEMBL1473881 0.87 FAAH (0.73) FAAHTP53HDAC6NPC1RAB9A
SCHEMBL1475365 0.86 FAAH (0.81) FAAHTP53HDAC3HDAC4HDAC1
SCHEMBL1473795 0.86 FAAH (0.66) FAAHTP53HDAC3HDAC4HDAC1
SCHEMBL1475291 0.86 NPC1 (0.71) FAAHTP53HDAC3HDAC4HDAC1
SCHEMBL1474976 0.85 FAAH (0.61) FAAHTP53HDAC3HDAC4HDAC1
SCHEMBL1476073 0.81 MAPT (0.63) FAAHTP53HDAC3HDAC1HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7915297-B2 Isoxazole derivatives and use thereof SK HOLDINGS CO., LTD. (KR) 2011-03-29 US disclosed
US-7915297-B2 Isoxazole derivatives and use thereof SK HOLDINGS CO., LTD. (KR) 2011-03-29 US disclosed
US-7915297-B2 Isoxazole derivatives and use thereof SK HOLDINGS CO., LTD. (KR) 2011-03-29 US disclosed
US-20090131336-A1 Isoxazole Derivatives and Use Thereof SK BIOPHARMACEUTICALS CO., LTD. (KR) 2009-05-21 US disclosed
US-20090131336-A1 Isoxazole Derivatives and Use Thereof SK BIOPHARMACEUTICALS CO., LTD. (KR) 2009-05-21 US disclosed
WO-2007078113-A1 ISOXAZOLE DERIVATIVES AND USE THEREOF SK HOLDINGS CO., LTD. (KR) 2007-07-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131336-A1 Isoxazole Derivatives and Use Thereof WNT3A, WNT1, WNT3 FAAH 4712/4885TP53 2830/4885HDAC3 849/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.